371917-16-7

Basic information

• Product Name: 1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane
• Synonyms: 1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane;(1-(trifluoromethyl)cyclobutyl)methanol
• CAS NO: 371917-16-7
• Molecular Formula: C₆H₉F₃O
• Molecular Weight: 154.1302696
• Mol File: 371917-16-7.mol

Chemical Properties

• Boiling Point: 124.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.273±0.06 g/cm3(Predicted)
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: 1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane(371917-16-7)
• EPA Substance Registry System: 1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane(371917-16-7)

Safety Data

• Hazardous Substances Data: 371917-16-7(Hazardous Substances Data)

Usage

Explanation

The compound consists of 6 carbon atoms, 9 hydrogen atoms, 3 fluorine atoms, and 1 oxygen atom.

Explanation

The compound is based on a four-membered cyclobutane ring, with additional functional groups attached to it.

Explanation

The compound has a hydroxyl (-OH) group and a trifluoromethyl (-CF3) group attached to the cyclobutane ring, giving it unique properties.

Explanation

1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane can be used as a starting material for the synthesis of various organic compounds.

Explanation

The compound has potential biological activities due to its unique structural features, making it a valuable tool in drug design and development.

Explanation

The presence of the trifluoromethyl group can improve the chemical and biological properties of the molecules synthesized using this compound.

Explanation

The cyclobutane ring in the compound provides rigidity and conformational constraint to the molecules, which can be beneficial in drug design and development.

Explanation

1-HydroxyMethyl-1-(trifluoroMethyl)cyclobutane has a wide range of applications in the fields of organic and medicinal chemistry, making it a valuable chemical.

Structure

Cyclobutane derivative

Functional groups

Hydroxyl and trifluoromethyl

Usage in organic synthesis

Building block

Usage in pharmaceutical research

Potential biological activities

Enhanced chemical and biological properties

Trifluoromethyl group

Rigidity and conformational constraint

Cyclobutane ring

Diverse applications

Organic and medicinal chemistry

Upstream product

• 277756-42-0 1-trifluoromethyl-cyclobutanecarbonyl fluoride 
• 1188909-22-9 methyl 1-(trifluoromethyl)cyclobutanecarboxylate 
• 277756-45-3 (1-trifluoromethyl)cyclobutanecarboxylic acid 

Downstream Products

• 1360569-08-9 (3R,4R,5S,6R)-2-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-07-8 (3R,4S,5S,6R)-2-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1360569-06-7 4-bromo-1-fluoro-2-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)benzene 
• 1360568-95-1 (3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360568-94-0 (3R,4S,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1360568-93-9 4-bromo-1-chloro-2-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)benzene 
• 1360569-43-2 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4, 5-triyl triacetate 
• 1360569-44-3 (2S,3R,4R,5S,6R)-2-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-35-2 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-36-3 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-( trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-33-0 (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(4-methyl-3-(4-((1-(trifluoromethyl)cyclobutyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1038404-00-0 (1-(trifluoromethyl)cyclobutyl)methyl 4-methylbenzenesulfonate 
• 371917-31-6 1-Formyl-1-(trifluoromethyl)cyclobutane 

Relevant articles and documents

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS

The invention relates to the cycloalkyl methoxybenzyl phenyl pyran derivatives as Sodium dependent glucose co transporter (SGLT) inhibitors, particularly SGLT2 and method of treating diseases, conditions and/or disorders inhibited by SGLT2 with them, and processes for preparing them.

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmacetical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

Routes from 1,1-cycloalkanedicarboxylic acids to geminal bis(polyfluoromethyl) substituted carbocycles

1-Fluoroformyl-1-(trifluoromethyl)cycloalkanes (1), prepared by treatment of 1,1-cycloalkane-dicarboxylic acids with SF4, were efficiently reduced to 1-hydroxymethyl-1-(trifluoromethyl)-cycloalkanes (2). Routes for the conversion of alcohols 2